Contrasting Codex DNA (NASDAQ:DNAY) and Nautilus Biotechnology (NASDAQ:NAUT)

Codex DNA (NASDAQ:DNAYGet Rating) and Nautilus Biotechnology (NASDAQ:NAUTGet Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

87.6% of Codex DNA shares are held by institutional investors. Comparatively, 47.9% of Nautilus Biotechnology shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Codex DNA and Nautilus Biotechnology’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Codex DNA $11.04 million 11.02 -$38.96 million ($2.28) -1.82
Nautilus Biotechnology N/A N/A -$50.31 million ($0.57) -5.79

Codex DNA has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Codex DNA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codex DNA and Nautilus Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Codex DNA -311.52% -46.56% -36.63%
Nautilus Biotechnology N/A -15.57% -14.77%

Analyst Ratings

This is a summary of current ratings and target prices for Codex DNA and Nautilus Biotechnology, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Codex DNA 0 0 3 0 3.00
Nautilus Biotechnology 0 2 2 0 2.50

Codex DNA presently has a consensus price target of $15.86, indicating a potential upside of 283.01%. Nautilus Biotechnology has a consensus price target of $8.67, indicating a potential upside of 162.63%. Given Codex DNA’s stronger consensus rating and higher probable upside, analysts clearly believe Codex DNA is more favorable than Nautilus Biotechnology.

Summary

Codex DNA beats Nautilus Biotechnology on 7 of the 11 factors compared between the two stocks.

About Codex DNA (Get Rating)

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

About Nautilus Biotechnology (Get Rating)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive News & Ratings for Codex DNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codex DNA and related companies with MarketBeat.com's FREE daily email newsletter.